Background
Dosimetric planning comparison study (IJROBP 2009). Evaluated intensity-modulated proton therapy (IMPT) vs photon IMRT for locally advanced NSCLC. Generated comparative dose-volume histograms for lung, heart, esophagus, and spinal cord across 10 patients with stage IIIA–IIIB NSCLC. Aimed to quantify the dosimetric advantage of proton therapy for thoracic malignancy where V20 lung and mean lung dose are the primary predictors of radiation pneumonitis. DOI: 10.1016/j.ijrobp.2008.10.084.
Interventions and follow up
Arm A: IMPT: 74 Gy(RBE) in 37 fractions using multi-field pencil-beam scanning optimizatio
Arm B: Photon IMRT: 74 Gy in 37 fractions (same prescription dose)
Primary endpoint: Dose-volume histogram comparison — lung V20, mean lung dose, esophageal Dmean, cardiac V30
mFollow up: N/A (dosimetric study)
Arm B: Photon IMRT: 74 Gy in 37 fractions (same prescription dose)
Primary endpoint: Dose-volume histogram comparison — lung V20, mean lung dose, esophageal Dmean, cardiac V30
mFollow up: N/A (dosimetric study)
Results
Mean lung dose (IMPT): 7.2 Gy(RBE) vs IMRT 12.4 Gy, P<.001
Lung V20 (IMPT): 19.8% vs IMRT 28.3%, P=.003
Esophageal Dmean (IMPT): Significantly lower
Cardiac V30 (IMPT): 4.2% vs IMRT 14.8%, P=.002
Lung V20 (IMPT): 19.8% vs IMRT 28.3%, P=.003
Esophageal Dmean (IMPT): Significantly lower
Cardiac V30 (IMPT): 4.2% vs IMRT 14.8%, P=.002
Adverse events
Main adverse events: N/A — dosimetric planning study. Reduction in mean lung dose and V20 with proton therapy is clinically predicted to reduce grade ≥2 radiation pneumonitis, which occurs in ~20–30% of photon IMRT patients and is the primary dose-limiting toxicity in NSCLC CRT.
Conclusions
IMPT achieves significantly lower dose to lungs, heart, and esophagus compared to photon IMRT for locally advanced NSCLC at equivalent tumor coverage. The dosimetric advantage is clinically meaningful: each 1 Gy reduction in mean lung dose reduces pneumonitis risk by ~3%. Proton therapy has the potential to reduce treatment-related mortality from radiation pneumonitis and cardiac toxicity in NSCLC.
Key Limitations
Key Limitations: Dosimetric study only — no clinical outcomes reported. Planning comparison on 10 patients may not represent the full range of NSCLC tumor locations and sizes. IMPT planning was expert-performed; real-world proton planning quality may vary. Clinical benefit requires prospective validation (NRG-LU001 trial).
Clinical Context
This and similar dosimetric studies form the basis for proton therapy in locally advanced NSCLC. Key indications: stage III NSCLC with large tumor volume where photon V20 >35% or mean lung dose >20 Gy, or superior sulcus tumors. NRG-LU001 RCT (proton vs photon for stage III NSCLC) was completed and confirms dosimetric advantages translate to clinical benefit.
References